Davis Polk advised the representatives of the underwriters in connection with the $511.5 million SEC-registered offering of 5,500,000 American Depositary Shares of BioNTech SE. In addition, the underwriters have an option to purchase up to an additional 825,000 ADSs. BioNTech is listed on the Nasdaq Global Select Market under the symbol “BNTX.”
Davis Polk is also advising the dealer managers and subscription agents in connection with BioNTech’s SEC-registered rights offering.
BioNTech is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. It exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Genevant, Fosun Pharma and Pfizer.
The Davis Polk capital markets team included partners Deanna L. Kirkpatrick and Yasin Keshvargar and associates John H. Runne, David Li and Prudence Ng. Partner Pritesh P. Shah and associates Tilak Koilvaram and Jennifer Leather provided intellectual property advice. Counsel Ethan R. Goldman provided tax advice. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the New York and Northern California offices.